Neuraxpharm attends 27th European Congress of Psychiatry
- Attendance at key European psychiatry summit underlines commitment to medical community
- CEO Dr. Jörg-Thomas Dierks to attend psychiatry Congress being held in Warsaw
April 5, 2019
Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces it will be attending the EPA 2019 Congress (27th European Congress of Psychiatry) from 6th - 9th April 2019 at the Expo XXI in Warsaw, Poland. Dr. Jörg-Thomas Dierks, CEO and members of the Neuraxpharm team will attend the Congress and host meetings.
Following the recent rebranding in 2018, Neuraxpharm is building on its expertise and vision as a true pan-European CNS focused specialty pharmaceutical company. Neuraxpharm is also able to bring its in-depth knowledge of the various markets where it has operated for more than 30 years as a reliable partner for healthcare professionals.
Neuraxpharm today has a direct presence in nine European countries. The recent launch of Neuraxpharm Polska is in line with its strategy to strengthen its leading position in the European CNS markets and have direct access to the Central and Eastern European (CEE) markets with its own sales force. As a result of its European expansion, the team will be attending the prestigious European Congress of Psychiatry for the first time.
Commenting on the event, Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, and a medical doctor himself, said: “We look forward to attending the EPA Congress, a forum of special importance to CNS specialists focused on improving mental health care. Our new operations in Poland reinforce our commitment to bringing diversified and affordable products to European markets. As this year’s event is being held in Warsaw, the EPA Congress also gives us an opportunity to connect with the international as well as local medical communities in this target growth region.”
Neuraxpharm offers and continues to develop a complete spectrum of therapeutic options in Depression, Psychosis / Schizophrenia, Epilepsy, Parkinson's, Alzheimer’s.
The 27th European Congress of Psychiatry is one of the leading events organised by the European Psychiatric Association (EPA), first founded in 1983. With active individual members in as many as 88 countries and 43 National Psychiatric Association Members who represent over 80,000 European psychiatrists, the EPA’s mission is to improve psychiatry and mental health care in Europe. The 2019 Congress will facilitate discussion and educational forums on a range of topics in the field of psychiatry, psychology, social work and clinical trials.
The Neuraxpharm team will host a stand at #EPA2019 from 6-9 April 2019 at the Expo XXI in Warsaw, Poland. To arrange a meeting or interview with the team please get in touch with firstname.lastname@example.org / email@example.com.
About EPA - European Psychiatry Association
The European Psychiatric Association (EPA) was founded in 1983. With active individual members in as many as 88 countries and 43 National Psychiatric Association Members who represent over 80,000 European psychiatrists, the EPA is the main association representing psychiatry in Europe. Its mission is to improve psychiatry and mental health care in Europe.
EPA members include leading experts in numerous fields. The EPA's activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development. Together, EPA members contribute to the life of the association and to the development of psychiatry in Europe. Each member has the possibility to actively contribute to ongoing projects and play a key role in shaping the future of the association and its policies. The 2019 EPA Congress is guided by this year’s motto: Psychiatry in Transition – Towards New Models, Goals and Challenges.